170 related articles for article (PubMed ID: 38688611)
61. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Cao S; Durrani FA; Rustum YM
Clin Cancer Res; 2004 Apr; 10(7):2561-9. PubMed ID: 15073137
[TBL] [Abstract][Full Text] [Related]
62. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.
Rick FG; Buchholz S; Schally AV; Szalontay L; Krishan A; Datz C; Stadlmayr A; Aigner E; Perez R; Seitz S; Block NL; Hohla F
Cell Cycle; 2012 Jul; 11(13):2518-25. PubMed ID: 22751419
[TBL] [Abstract][Full Text] [Related]
63. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941
[TBL] [Abstract][Full Text] [Related]
64. Colon-cancer liver metastasis is effectively targeted by recombinant methioninase (rMETase) in an orthotopic mouse model.
Miyake K; Han Q; Murakami T; Kiyuna T; Kawaguchi K; Igarashi K; Lwin TM; Miyake M; Yamamoto J; Bouvet M; Endo I; Hoffman RM
Tissue Cell; 2023 Aug; 83():102125. PubMed ID: 37320867
[TBL] [Abstract][Full Text] [Related]
65. Afterword: Oral Methioninase-Answer to Cancer and Fountain of Youth?
Hoffman RM; Han Q; Kawaguchi K; Li S; Tan Y
Methods Mol Biol; 2019; 1866():311-322. PubMed ID: 30725426
[TBL] [Abstract][Full Text] [Related]
66. Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells.
Ishizu K; Sunose N; Yamazaki K; Tsuruo T; Sadahiro S; Makuuchi H; Yamori T
Biol Pharm Bull; 2007 Sep; 30(9):1779-83. PubMed ID: 17827739
[TBL] [Abstract][Full Text] [Related]
67. The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance.
Quackenbush KS; Bagby S; Tai WM; Messersmith WA; Schreiber A; Greene J; Kim J; Wang G; Purkey A; Pitts TM; Nguyen A; Gao D; Blatchford P; Capasso A; Schuller AG; Eckhardt SG; Arcaroli JJ
Oncotarget; 2016 May; 7(19):28273-85. PubMed ID: 27070088
[TBL] [Abstract][Full Text] [Related]
68. Histone methylation status of H3K4me3 and H3K9me3 under methionine restriction is unstable in methionine-addicted cancer cells, but stable in normal cells.
Yamamoto J; Han Q; Inubushi S; Sugisawa N; Hamada K; Nishino H; Miyake K; Kumamoto T; Matsuyama R; Bouvet M; Endo I; Hoffman RM
Biochem Biophys Res Commun; 2020 Dec; 533(4):1034-1038. PubMed ID: 33019978
[TBL] [Abstract][Full Text] [Related]
69. Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo.
Pohl M; Stricker I; Schoeneck A; Schulmann K; Klein-Scory S; Schwarte-Waldhoff I; Hasmann M; Tannapfel A; Schmiegel W; Reinacher-Schick A
J Cancer Res Clin Oncol; 2009 Oct; 135(10):1377-86. PubMed ID: 19340455
[TBL] [Abstract][Full Text] [Related]
70. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
71. Oral Recombinant Methioninase Sensitizes a Bladder Cancer Orthotopic Xenograft Mouse Model to Low-dose Cisplatinum and Prevents Metastasis.
Sun YU; Nishino H; Sugisawa N; Yamamoto J; Hamada K; Zhu G; Lim HI; Hoffman RM
Anticancer Res; 2020 Nov; 40(11):6083-6091. PubMed ID: 33109546
[TBL] [Abstract][Full Text] [Related]
72. Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model.
Higuchi T; Han Q; Miyake K; Oshiro H; Sugisawa N; Tan Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biochem Biophys Res Commun; 2020 Feb; 523(1):135-139. PubMed ID: 31839218
[TBL] [Abstract][Full Text] [Related]
73. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
[TBL] [Abstract][Full Text] [Related]
74. Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet.
Kubota Y; Han Q; Hamada K; Aoki Y; Masaki N; Obara K; Tsunoda T; Hoffman RM
Anticancer Res; 2022 Aug; 42(8):3857-3861. PubMed ID: 35896248
[TBL] [Abstract][Full Text] [Related]
75. High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate.
Ma H; Li X; Yang Z; Okuno S; Kawaguchi T; Yagi S; Bouvet M; Hoffman RM
J Surg Res; 2011 Dec; 171(2):684-90. PubMed ID: 20851421
[TBL] [Abstract][Full Text] [Related]
76. Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
Aoki Y; Tome Y; Wu NF; Yamamoto J; Hamada K; Han Q; Bouvet M; Nishida K; Hoffman RM
Anticancer Res; 2021 Apr; 41(4):1745-1751. PubMed ID: 33813378
[TBL] [Abstract][Full Text] [Related]
77. Recombinant-methioninase-producing
Kubota Y; Han Q; Morinaga S; Mizuta K; Bouvet M; Tsunoda T; Hoffman RM
Cancer Diagn Progn; 2023; 3(6):649-654. PubMed ID: 37927811
[TBL] [Abstract][Full Text] [Related]
78. Tumor regression achieved by encapsulating a moderately soluble drug into a polymeric thermogel.
Ci T; Chen L; Yu L; Ding J
Sci Rep; 2014 Jul; 4():5473. PubMed ID: 24980734
[TBL] [Abstract][Full Text] [Related]
79. The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.
Zhu H; Zhao F; Yu S; He J; Deng L; Yi C; Huang Y
Int J Mol Med; 2012 Nov; 30(5):1087-94. PubMed ID: 22922573
[TBL] [Abstract][Full Text] [Related]
80. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
